Review



parental pc9 cells  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    MedChemExpress parental pc9 cells
    Experimental validation of the function of ACTN1 in inducing EGFR-TKI resistance and malignant phenotypes in the <t>PC9</t> cell line. (A) Osimertinib-resistant and parental PC9 lung adenocarcinoma cell lines (designated PC9-P and PC9-OR) are treated with osimertinib, followed by CCK-8 assays. (B) Representative images of PC9-P and PC9-OR cells under a 10× microscope. (C) A bar plot reveals the result of qPCR, illustrating relative mRNA expression levels of ACTN1 in PC9-P and PC9-OR cell lines. (D,E) Western blotting shows ACTN1-silencing efficiency in PC9-OR cells. Quantification is performed using ImageJ software. (F) PC9-OR and ACTN1-silenced PC9-OR cells are treated with osimertinib, and their sensitivities are assessed by CCK-8 assays. (G) CCK8-assays are conducted in primary and ACTN1-silenced PC9-OR cells. Cellular viabilities of all cell groups within 5 days are quantified by optical density (OD) values at 450 nm and depicted in a line chart. (H,I) Transwell migration assays are conducted in primary and ACTN1-silenced PC9-OR cells. The number of migration cells are counted using ImageJ software. ( p -value ≥0.05, ns; p -value <0.05, *; p -value <0.01, **; p -value <0.001, ***; p -value <0.0001, ****).
    Parental Pc9 Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 198 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/parental+pc9+cells/pmc13122775-134-1-18?v=MedChemExpress
    Average 97 stars, based on 198 article reviews
    parental pc9 cells - by Bioz Stars, 2026-08
    97/100 stars

    Images

    1) Product Images from "Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance"

    Article Title: Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance

    Journal: Frontiers in Cell and Developmental Biology

    doi: 10.3389/fcell.2026.1738641

    Experimental validation of the function of ACTN1 in inducing EGFR-TKI resistance and malignant phenotypes in the PC9 cell line. (A) Osimertinib-resistant and parental PC9 lung adenocarcinoma cell lines (designated PC9-P and PC9-OR) are treated with osimertinib, followed by CCK-8 assays. (B) Representative images of PC9-P and PC9-OR cells under a 10× microscope. (C) A bar plot reveals the result of qPCR, illustrating relative mRNA expression levels of ACTN1 in PC9-P and PC9-OR cell lines. (D,E) Western blotting shows ACTN1-silencing efficiency in PC9-OR cells. Quantification is performed using ImageJ software. (F) PC9-OR and ACTN1-silenced PC9-OR cells are treated with osimertinib, and their sensitivities are assessed by CCK-8 assays. (G) CCK8-assays are conducted in primary and ACTN1-silenced PC9-OR cells. Cellular viabilities of all cell groups within 5 days are quantified by optical density (OD) values at 450 nm and depicted in a line chart. (H,I) Transwell migration assays are conducted in primary and ACTN1-silenced PC9-OR cells. The number of migration cells are counted using ImageJ software. ( p -value ≥0.05, ns; p -value <0.05, *; p -value <0.01, **; p -value <0.001, ***; p -value <0.0001, ****).
    Figure Legend Snippet: Experimental validation of the function of ACTN1 in inducing EGFR-TKI resistance and malignant phenotypes in the PC9 cell line. (A) Osimertinib-resistant and parental PC9 lung adenocarcinoma cell lines (designated PC9-P and PC9-OR) are treated with osimertinib, followed by CCK-8 assays. (B) Representative images of PC9-P and PC9-OR cells under a 10× microscope. (C) A bar plot reveals the result of qPCR, illustrating relative mRNA expression levels of ACTN1 in PC9-P and PC9-OR cell lines. (D,E) Western blotting shows ACTN1-silencing efficiency in PC9-OR cells. Quantification is performed using ImageJ software. (F) PC9-OR and ACTN1-silenced PC9-OR cells are treated with osimertinib, and their sensitivities are assessed by CCK-8 assays. (G) CCK8-assays are conducted in primary and ACTN1-silenced PC9-OR cells. Cellular viabilities of all cell groups within 5 days are quantified by optical density (OD) values at 450 nm and depicted in a line chart. (H,I) Transwell migration assays are conducted in primary and ACTN1-silenced PC9-OR cells. The number of migration cells are counted using ImageJ software. ( p -value ≥0.05, ns; p -value <0.05, *; p -value <0.01, **; p -value <0.001, ***; p -value <0.0001, ****).

    Techniques Used: Biomarker Discovery, CCK-8 Assay, Microscopy, Expressing, Western Blot, Software, Migration



    Similar Products

    parental pc9 cells  (MedChemExpress)
    97
    MedChemExpress parental pc9 cells
    Experimental validation of the function of ACTN1 in inducing EGFR-TKI resistance and malignant phenotypes in the <t>PC9</t> cell line. (A) Osimertinib-resistant and parental PC9 lung adenocarcinoma cell lines (designated PC9-P and PC9-OR) are treated with osimertinib, followed by CCK-8 assays. (B) Representative images of PC9-P and PC9-OR cells under a 10× microscope. (C) A bar plot reveals the result of qPCR, illustrating relative mRNA expression levels of ACTN1 in PC9-P and PC9-OR cell lines. (D,E) Western blotting shows ACTN1-silencing efficiency in PC9-OR cells. Quantification is performed using ImageJ software. (F) PC9-OR and ACTN1-silenced PC9-OR cells are treated with osimertinib, and their sensitivities are assessed by CCK-8 assays. (G) CCK8-assays are conducted in primary and ACTN1-silenced PC9-OR cells. Cellular viabilities of all cell groups within 5 days are quantified by optical density (OD) values at 450 nm and depicted in a line chart. (H,I) Transwell migration assays are conducted in primary and ACTN1-silenced PC9-OR cells. The number of migration cells are counted using ImageJ software. ( p -value ≥0.05, ns; p -value <0.05, *; p -value <0.01, **; p -value <0.001, ***; p -value <0.0001, ****).
    Parental Pc9 Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/parental+pc9+cells/pmc13122775-134-1-18?v=MedChemExpress
    Average 97 stars, based on 1 article reviews
    parental pc9 cells - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    retroviral transduction pc9 parental cells  (ATCC)
    99
    ATCC retroviral transduction pc9 parental cells
    Experimental validation of the function of ACTN1 in inducing EGFR-TKI resistance and malignant phenotypes in the <t>PC9</t> cell line. (A) Osimertinib-resistant and parental PC9 lung adenocarcinoma cell lines (designated PC9-P and PC9-OR) are treated with osimertinib, followed by CCK-8 assays. (B) Representative images of PC9-P and PC9-OR cells under a 10× microscope. (C) A bar plot reveals the result of qPCR, illustrating relative mRNA expression levels of ACTN1 in PC9-P and PC9-OR cell lines. (D,E) Western blotting shows ACTN1-silencing efficiency in PC9-OR cells. Quantification is performed using ImageJ software. (F) PC9-OR and ACTN1-silenced PC9-OR cells are treated with osimertinib, and their sensitivities are assessed by CCK-8 assays. (G) CCK8-assays are conducted in primary and ACTN1-silenced PC9-OR cells. Cellular viabilities of all cell groups within 5 days are quantified by optical density (OD) values at 450 nm and depicted in a line chart. (H,I) Transwell migration assays are conducted in primary and ACTN1-silenced PC9-OR cells. The number of migration cells are counted using ImageJ software. ( p -value ≥0.05, ns; p -value <0.05, *; p -value <0.01, **; p -value <0.001, ***; p -value <0.0001, ****).
    Retroviral Transduction Pc9 Parental Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/parental+pc9+cells/pm29909007-28-8-53?v=ATCC
    Average 99 stars, based on 1 article reviews
    retroviral transduction pc9 parental cells - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Experimental validation of the function of ACTN1 in inducing EGFR-TKI resistance and malignant phenotypes in the PC9 cell line. (A) Osimertinib-resistant and parental PC9 lung adenocarcinoma cell lines (designated PC9-P and PC9-OR) are treated with osimertinib, followed by CCK-8 assays. (B) Representative images of PC9-P and PC9-OR cells under a 10× microscope. (C) A bar plot reveals the result of qPCR, illustrating relative mRNA expression levels of ACTN1 in PC9-P and PC9-OR cell lines. (D,E) Western blotting shows ACTN1-silencing efficiency in PC9-OR cells. Quantification is performed using ImageJ software. (F) PC9-OR and ACTN1-silenced PC9-OR cells are treated with osimertinib, and their sensitivities are assessed by CCK-8 assays. (G) CCK8-assays are conducted in primary and ACTN1-silenced PC9-OR cells. Cellular viabilities of all cell groups within 5 days are quantified by optical density (OD) values at 450 nm and depicted in a line chart. (H,I) Transwell migration assays are conducted in primary and ACTN1-silenced PC9-OR cells. The number of migration cells are counted using ImageJ software. ( p -value ≥0.05, ns; p -value <0.05, *; p -value <0.01, **; p -value <0.001, ***; p -value <0.0001, ****).

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance

    doi: 10.3389/fcell.2026.1738641

    Figure Lengend Snippet: Experimental validation of the function of ACTN1 in inducing EGFR-TKI resistance and malignant phenotypes in the PC9 cell line. (A) Osimertinib-resistant and parental PC9 lung adenocarcinoma cell lines (designated PC9-P and PC9-OR) are treated with osimertinib, followed by CCK-8 assays. (B) Representative images of PC9-P and PC9-OR cells under a 10× microscope. (C) A bar plot reveals the result of qPCR, illustrating relative mRNA expression levels of ACTN1 in PC9-P and PC9-OR cell lines. (D,E) Western blotting shows ACTN1-silencing efficiency in PC9-OR cells. Quantification is performed using ImageJ software. (F) PC9-OR and ACTN1-silenced PC9-OR cells are treated with osimertinib, and their sensitivities are assessed by CCK-8 assays. (G) CCK8-assays are conducted in primary and ACTN1-silenced PC9-OR cells. Cellular viabilities of all cell groups within 5 days are quantified by optical density (OD) values at 450 nm and depicted in a line chart. (H,I) Transwell migration assays are conducted in primary and ACTN1-silenced PC9-OR cells. The number of migration cells are counted using ImageJ software. ( p -value ≥0.05, ns; p -value <0.05, *; p -value <0.01, **; p -value <0.001, ***; p -value <0.0001, ****).

    Article Snippet: Briefly, parental PC9 cells in the logarithmic growth phase were exposed to gradually increasing concentration of osimertinib (#HY-15772, MedChemExpress, China).

    Techniques: Biomarker Discovery, CCK-8 Assay, Microscopy, Expressing, Western Blot, Software, Migration